Hims expansion may not come in time for risky GLP-1 business
ZEROBYTE
Hims' expansion into the GLP-1 market is risky, with timing, regulation, and competition posing challenges. Can they succeed?
Biotechnology
Governing Biotechnology’s Dual-Use Security Dilemma
Exploring the dual-use dilemma in biotechnology, challenges in governance, and the role of technology in ensuring global security.
My biggest GLP-1 ethical problem: patients who don’t want to stop
Exploring the ethical challenges of prolonged GLP-1 usage in patients who fear discontinuation and the responsibilities of healthcare providers.
Global biotechnology leader joins the Novo Nordisk Foundation as Vice President
A global biotechnology leader joins Novo Nordisk Foundation as VP, signaling new opportunities for innovation and sustainability in healthcare.
CDC issues travel alert for Seychelles due to chikungunya
CDC issues travel alert for Seychelles due to chikungunya outbreak, advising travelers on precautions to ensure safety.
How to help a snakebite victim? Doctors explain
How to help a snakebite victim? Doctors explain
AI weapons against HIV, influenza, RSV, and COVID-19: Breakthroughs and big risks
AI Weapons Against HIV, Influenza, RSV, and COVID-19: Breakthroughs and Big Risks
Artificial intelligence could end disease, lead to “radical abundance,” Google DeepMind CEO Demis Hassabis says
Artificial intelligence could end disease, lead to "radical abundance," Google DeepMind CEO Demis Hassabis says
More Americans are turning to AI for health advice
More Americans are Turning to AI for Health Advice
AI-powered blood test improves early Lyme disease detection
AI-powered Blood Test Improves Early Lyme Disease Detection.